Category: Epidarex Portfolio News
Highlights from the publication include: Collaboration with AZ on kinase inhibitor induced cardiotoxicity Understanding E-C coupling is essential in kinase research CellOPTIQ® is the only single mechanistic screen providing insight into E-C coupling mechanism Observing the interplay between voltage, calcium transient and contractility is vital…
Raises £2 million from Epidarex Capital to progress pipeline of IgE antibody drug candidates to treat cancer IgE antibodies shown to offer greater efficacy than IgG comparator in cancer models Dr. Tim Wilson appointed Chief Executive Officer London, 20 June 2017 – IGEM Therapeutics (IGEM),…
Dr Moore was Founder Chairman of Mission Therapeutics and PsiOxus Therapeutics with each of which he continues to serve as a non-executive director. He also holds non-executive positions with Chronos Therapeutics and NASDAQ-listed Trillium Therapeutics Inc. Dr Moore was previously CEO of Piramed Limited, a…
Brighton, UK, April 5, 2017 – Enterprise Therapeutics Ltd, a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases, has won funding from the Cystic Fibrosis Trust to identify new drug mechanisms for the treatment of cystic…
Hamburg, April 4, 2017 – Topas Therapeutics GmbH (“Topas”), a privately held biotech company pursuing a novel liver-based immune tolerance approach, today announced the election of Paul Sekhri as Chairman of the Board effective immediately. Paul Sekhri is currently CEO and President of the US…
Edinburgh, United Kingdom, February 27, 2017 – Caldan Therapeutics, a spin-out company from the Universities of Glasgow and Southern Denmark, which specialises in developing novel therapeutics targeting free fatty acid receptors for the treatment of metabolic disease, including Type 2 Diabetes and non-alcoholic steatohepatitis (NASH),…
Baltimore, MD, February 21, 2017 – Harpoon Medical, Inc., a clinical stage medical device company focused on the development and commercialization of transcatheter beating heart mitral valve repair technology, announced today that the company has hired Laura Brenton to serve as Vice President of Clinical Affairs. …
Glasgow, Scotland, 30th January 2017: Mironid® Limited, a leader in cell signalling-directed drug discovery, is delighted to start the New Year by initiating a £606K programme to expand its repertoire of proprietary LoAc® molecules. The work will be 70% funded by the UK’s innovation agency,…